AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03743597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigvaris COTTON
Description: Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other
Study NCT04091945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LT3001 Drug Product
Description: Active comparator
Study NCT04091945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT02228083 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine with epinephrine
Description: Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
Study NCT02228083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with epinephrine
Description: Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
Study NCT03946319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Introspect Health
Description: Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools. The software is delivered via the internet using a mobile device or computer.
Study NCT03946319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Introspect Health
Description: Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools. The software is delivered via the internet using a mobile device or computer.
Study NCT00866281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
Study NCT03426618 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study NCT01588769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALECSAT cell based immunotherapy
Description: I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
Study NCT03010384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Study NCT04412109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization for postoperative pain control
Study NCT02678793 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CNTX-4975
Study NCT01630187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Administration of carbetocin 50 mcg , after clamping the umbilical cord
Study NCT01630187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Administration of carbetocin 100 mcg , after clamping the umbilical cord
Study NCT04439474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.
Study NCT04439474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: In this group, patients receive their usual medications and treatments
Study NCT02746718 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: A blood sample for CPK dosage and pompe disease test
Study NCT03039504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potensa, a succinate-based dietary supplement
Description: Potensa - a dietary supplement: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
Study NCT03039504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
Study NCT01833481 — intervention group
Intervention type: RADIATION
Intervention: Fluoroscopy surveillance of patients while walking
Description: While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
Study NCT01731132 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel IUD or Copper IUD
Description: Women who initiate the use of an IUD at the time of the study.
Study NCT03216122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional/Delayed Loading
Study NCT03216122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Loading
Study NCT04090060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Self-/Companion Exams
Description: 300 men and 50 couples will be randomized and encouraged to practice anal exams at home before Visit 2. Practice results will be elicited by staff. They will return for Visit 2 (six months after Visit 1). At Visit 2, they will complete a pre- and post-visit computer assisted self-interview. They will receive written instructions. After completing an anal self-exam or anal companion exam at home, they will record the results. At the clinic, they will have a Digital Anal Rectal Exam (DARE) by a clinician who will give the subject his results.
Study NCT04090060 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Arm
Description: 300 individuals and 50 couples will be randomized to this arm. Following Visit 1, they will neither be encouraged nor discouraged from practicing self- or companion exam. They will return for Visit 2 (six months after Visit 1). They will receive written anal exam instructions. They will then complete the self- or companion exam at home, and record the results. At the clinic, they will receive a clinician DARE. Clinicians will give DARE results. Persons will take a post-exam computer-assisted self-interview. Persons in this arm (control) will be asked if they have performed exams between visits.
Study NCT01447550 — intervention group
Intervention type: DRUG
Intervention: Bosentan
Description: Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
Study NCT02619630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil >1 Giga/Liter~for a maximum of 5 blocks
Study NCT02734537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02734537 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02734537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01472042 — intervention group
Intervention type: OTHER
Intervention: Banyan Biomarkers
Description: Biomarkers to detect specific proteins.
Study NCT01203514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.
Study NCT01203514 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
Study NCT01001273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic Normoglycemic Clamp
Description: The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
Study NCT00961350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA32540
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
Study NCT00961350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC Aspirin 325
Description: The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
Study NCT00571727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mecasermin
Description: injections BID of rhIGF-1, mecasermin
Study NCT02954601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORMD-0801 (qd)
Description: Dose 1 = ORMD-0801 (qd)
Study NCT02954601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORMD-0801 (bid)
Description: Dose 2 = ORMD-0801 (bid)
Study NCT02954601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORMD-0801 (tid)
Description: Dose 3 = ORMD-0801 (tid)
Study NCT02954601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: fish oil placebo
Study NCT01837511 — intervention group
Intervention type: OTHER
Intervention: Data acquisition and analysis
Description: Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
Study NCT00634803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive behavioral therapy
Study NCT00634803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine/naloxone
Study NCT00634803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: buprenorphine/naloxone
Study NCT00634803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Counseling
Description: Didactic, lecture-discussion format to supplement information and advice provided by physicians
Study NCT00634803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician Management
Description: Brief physician counseling
Study NCT03349060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
Study NCT03349060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
Study NCT03349060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Study NCT01770769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemi - arthroplasty
Description: modular hemiarthroplasty
Study NCT01770769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: internal fixation
Description: Two cancellous parallel screws - internal fixation of the femoral neck fracture
Study NCT04405492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.
Description: After inclusion, demographic and medical data will be collected. Evaluated point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Clinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different clinical samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care.
Study NCT04405492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.
Description: After inclusion, demographic and medical data will be collected. Point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken (D0). A follow-up at D15, M1, M3, M6, M9 will be done. At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.~Cinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care.
Study NCT04405492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capillary and salivary sampling
Description: Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.
Study NCT01288677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128
Description: Escalated doses
Study NCT01002989 — intervention group
Intervention type: DEVICE
Intervention: Doppler Ankle-Brachial Index measurement
Description: Measurement of the Ankle-Brachial Index by Doppler.
Study NCT01002989 — intervention group
Intervention type: DEVICE
Intervention: WatchBP Office Ankle-Brachial Index measurement.
Description: Measurement of Ankle-Brachial Index by WatchBP Office device.
Study NCT02920502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 2: cholecalciferol 50,000 IU
Description: One time dose of cholecalciferol 50,000 IU
Study NCT02920502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 3: cholecalciferol 100,000 IU
Description: One time dose of cholecalciferol 100,000 IU
Study NCT02920502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 4: cholecalciferol 200,000 IU
Description: One time dose of cholecalciferol 200,000 IU
Study NCT02920502 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arm 1: Placebo
Description: One time dose of Placebo
Study NCT01072773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2, by IV on days 1, 8 and 15 every 28 days
Study NCT01072773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 300 mg/m\^2, orally, on days 1, 8, 15 \& 22 every 28 days.
Study NCT01072773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg, orally, on days 1, 8, 15 \& 22 every 28 days
Study NCT02588794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb 300 ml device (3804606CE01)
Description: additional cytokine adsorber
Study NCT04455087 — intervention group
Intervention type: OTHER
Intervention: sensitization
Description: sensitization of doctor to decrease the prescription of abuse exams
Study NCT00961571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib and capecitabine
Description: Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
Study NCT02044120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib
Study NCT02044120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT02044120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT04236492 — intervention group
Intervention type: PROCEDURE
Intervention: Fresh osteochondral allografting
Description: Transplantation of a fresh osteochondral allograft in the knee
Study NCT00497523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Study NCT00497523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate/Salbutamol combination
Study NCT00497523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Study NCT04276961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be given for a total of 12 session over 4 weeks. Acupuncture at acupoints Tianshu (ST25), Shangjuxu (ST37), Zusanli (ST36), and Neiguan (PC6) bilaterally will be given.
Study NCT04276961 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be given for a total of 12 session over 4 weeks. Acupuncture at acupoints Tianshu (ST25), Shangjuxu (ST37), Zusanli (ST36), and Neiguan (PC6) bilaterally will be given.
Study NCT01812460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention-training-group
Description: As descriped in Arm Description
Study NCT02940262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT02940262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02940262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET imaging
Study NCT03944668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 36 sessions of comprehensive cardiac rehabilitation over 12 weeks
Study NCT03548961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy
Study NCT01846364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diindolylmethane (DIM)
Description: 300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
Study NCT00380133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB681323
Description: 5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
Study NCT00380133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
Study NCT00380133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets matched to SB681323 or prednisolone
Study NCT04084418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
Study NCT03797768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural-FCHV Visit
Description: Female Community Health Volunteer will visit selected households on average 3 times a year for providing health promotion messages on improving lung health status and avoiding risk factors to COPD.
Study NCT04084418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLCHF Diet
Description: Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
Study NCT03809754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention under OCT
Description: After randomization, subjects receive primary PCI under the guiding of OCT
Study NCT03809754 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous Coronary Intervention under Angiography
Description: After randomization, subjects receive primary PCI under the guiding of angiography
Study NCT01372995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral Vitamin D3 50,000 IU
Description: Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)
Study NCT01372995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral Vitamin D3 100,000IU
Description: Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)